A Christmas Message to the DEA's Diversion Anti Marijuana Cabal
This Christmas season, President Trump's executive action to advance rescheduling and medical research has finally exposed the truth: the DEA marijuana obstruction was never about public safety. It was about ideology. Control. And a refusal to accept science that challenged long held dogma.
WASHINGTON, DC, December 26, 2025 (Newswire.com) - As the holiday season arrives-a time traditionally reserved for reflection, humility, and compassion-we extend a Merry Christmas to the small but powerful group of Drug Enforcement Administration diversion officials whose decisions have defined the last seven years of federal marijuana policy: Anne Milgram, Thomas Prevoznik, Matthew Strait, Thomas Cook, and Aarathi Haig.
This is not a greeting of celebration. It is a message of reckoning-and, still, of hope.
For years, this group formed the core of an internal resistance that obstructed FDA-authorized medical cannabis research, despite congressional mandates, bipartisan pressure, and mounting scientific evidence. While the rest of the federal government-HHS, NIH, FDA-moved cautiously toward science, this cabal chose delay, procedural traps, and administrative sabotage.
The result was not abstract.
Patients with Huntington's Disease, a fatal neurodegenerative disorder with no cure.
Patients with Multiple Sclerosis, enduring progressive disability, pain, and spasticity.
Patients whose physicians were ready to study standardized cannabinoid medicines-only to be blocked by an agency charged with enabling research, not preventing it.
For seven years, these patients waited while paperwork was weaponized.
The DEA demanded "bona fide supply agreements" that federal law itself made impossible to obtain. It forced applicants into an administrative law system later acknowledged by the Department of Justice to be constitutionally defective. It ignored statutory timelines measured in days, stretching them into thousands.
And while patients waited, the irony grew unbearable.
Cartels flourished.
Synthetic THC flooded gas stations.
Unregulated high-potency products proliferated.
Yet the one pathway that could have delivered pharmaceutical-grade, FDA-regulated, non-smoked cannabinoid medicine was deliberately stalled.
This Christmas season, President Trump's executive action to advance rescheduling and medical research has finally exposed the truth: the DEA marijuana obstruction was never about public safety. It was about ideology. Control. And a refusal to accept science that challenged long held dogma.
So yes-Merry Christmas.
And we sincerely hope that the spirit of the season does what bureaucratic power never could: soften hardened positions.
We hope it brings reflection on what it means to deny research to dying patients.
On what it means to delay medicine while claiming to protect health.
On what it means to wield authority without accountability.
History is already rendering its verdict. The federal government has now acknowledged accepted medical use. The research will proceed. The medicine will be studied. The patients will no longer be ignored.
Redemption, however, is still available.
It begins with acknowledging harm.
It continues with humility.
And it ends-perhaps-with an apology not to companies, but to patients.
From those who have spent years fighting for science, for law, and for people suffering in silence:
Merry Christmas.
May the season bring the healing that policy long denied.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
Source: MMJ International Holdings
Share:
Tags: botanical drug development, cannabinoid drug development, cannabis compassion patients, cannabis rescheduling, cannabis research barriers removed, cannabis soft gel capsules, Christmas message medical cannabis, chronic pain treatment alternatives, DEA cannabis policy, DEA obstruction cannabis, Duane Boise, Duane Boise DEA, Duane Boise jamaica, Duane Boise net worth, FDA cannabinoid research, FDA clinical trials cannabis, federal cannabis reform, federally legal cannabis medicine, final dose form cannabinoid, GMP cannabinoid medicine, Huntington’s disease treatment, medical cannabis science, medical marijuana patients, medical marijuana research, multiple sclerosis treatment, neurological disorder therapy, non-smoked cannabinoid medicine, opioid crisis alternatives, pharmaceutical cannabis, president trump executive order, President Trump rescheduling, public health cannabis reform, schedule III marijuana, science-based cannabis policy, veterans medical cannabis